Experts in chengdu focus disease model and new drug research and development at home and abroad
 
 
Release date: 2014-11-01 

 
Source: People's Daily online 

        Chengdu People's Daily on November 1 (Xiong Wenyao) today, BioTianfu innovation in drug research and disease model international BBS held in chengdu high-tech zone. From Europe and the United States and mainland China in the field of clinical medicine, drug development and drug approval well-known experts and professors, metabolic system diseases, diseases of the immune system and central nervous system disease and other major areas of innovative medicine and disease model for communication and discussion. 
 
        Promoting the new drug r&d process focused on disease model 
 
        On the BBS, innovative drug development trends and ideas, how to promote the innovative development of the biomedicine industry, become the participants on topics of mutual interest. From west China hospital of sichuan university, third military medical university, fudan university school of medicine, Covance companies in the United States, the United States medical school at the university of Florida, Merck Research Laboratories Merck Research Laboratories, the ministry of science and technology at the university of Washington school of medicine, the British national institute for medical Research and other international medical institutions, Laboratories and Research institutes of 14 experts and scholars, mainly on human major disease models based on non-human primates and new drug development and delivered a keynote speech in related field. 
 
        "Biological medicine field top scientific research institutes at home and abroad, major parks and laboratory cooperation has become the necessary approach for the new drug research and development." Sichuan at the biological technology group co., LTD. President Ceng Wen said, the international BBS to strengthen the research and development of the world's end in the depth of the niche cooperation, further improve represented by at the biological medicine industry in sichuan in nonhuman primates human major disease model based drug discovery screening technology platform construction work. 
 
        It is understood that the technology platform has been established the major of primary primate animal models of human diseases, disease background database, the future can be formed on a global scale is very precious, valuable resources innovation medicine research and development of animal disease model. Once said, the participating experts highly agree with the important value of the technology platform, at the same time, in sichuan, chengdu biological pharmaceutical industry development environment, development policy is also given full recognition, "held by the BBS, we have agreed with the global multilateral cooperation intention, this to promote sichuan and the world in the field of new drug research and development will play a promote role." 
 
        With biological industry gathered nearly 600 enterprises 
 
        "Biological medicine research and development is a long game, build support research and development process of the innovation system and carrier is very important." , according to the relevant person in charge of chengdu high-tech zone at present, chengdu high-tech zone has been initially formed before including drug discovery, drug development, clinical evaluation, clinical test, pilot production, etc. The whole process of new drug research and development system. Including preclinical studies (GLP) public technology platform, biomedicine analysis test of public technology platform, natural medicine engineering and technology research of public technology platform, leading drug development platform, biological medicine class public technology platform to 21. 
 
        Area there are in research project (237 drugs and medical devices), among them, including mondial nine acquisitive vial multi-function apoptosis agonists (DATR), chapter nine biological anti-cancer chemical class of drugs "chlorogenic acid for injection" and so on six class of new drugs in clinical stage. 
 
        In terms of carrier construction, chengdu high-tech zone has built two biological professional park, tianfu life science park and tianhe biological medicine incubator. By the end of 2013, the chengdu high-tech zone has gathered 595 biological enterprises, industry professionals 25000 people, among them, the master's degree or above in more than 2000 people, the national "one thousand project" talent nine people; Industry covers an area of about 2 square kilometers, was awarded the national science and technology industrial base for TCM modernization, national biological industry base in chengdu, chengdu national medicine export base, chengdu national biomedical materials and medical equipment high-tech industrialization base. 
 
        In addition, in the first three quarters of this year, chengdu high-tech zone of biological industry fast development, the industrial added value growth of 23.7%. By September this year, chengdu high-tech zone of biological industry has rules on 38 industrial enterprises, realize the industrial output value 7.05 billion yuan, up 24% from a year earlier. Industrial output 2.97 billion yuan, up 26% from a year earlier. This year on September 20, chengdu high-tech zone has issued a "support the strategic emerging industry enterprises to speed up the development of a number of policy, biological industry is one of its strategic directions. At present, chengdu high-tech zone has become a famous of biological pharmaceutical enterprises in western China are preferred.
 
The original link: http://politics.scdaily.cn/gdbb/content/2014-11/01/content_9508420.htm